Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals
CA 2334895 C · Owner: Mount Sinai School Of Medicine · Inventors: Muster, Thomas; Garcia-Sastre, Adolfo; Palese, Peter
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates, in general to attenuated negative-strand RNA , viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. The invention also relates to the development and use of IFNdeficient systems for selection of such attenuated viruses. In particular the , invention relates to attenuated influenza viruses having modifications to the NS1 gene that diminish or eliminate the ability of the NS1 gene product to antagonize the cellular IFN response. The mutant viruses replicate in vivo but demonstrate reduced pathogenicity, and therefore are well suited for …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 11, 1999 and granted January 19, 2016. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended June 11, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 11, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.